中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01177 中国生物制药

休市中 11-13 16:08:17

5.560

-0.010

-0.18%

最高5.650	最低5.465	成交量8,131万
今开5.570	昨收5.570	日振幅3.32%
总市值1,039亿	流通市值1,039亿	总股本186.83亿
成交额4.53亿	换手率0.44%	流通股本186.83亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01177","market":"HK","secType":"STK","nameCN":"中国生物制药","latestPrice":5.56,"timestamp":1794557297004,"preClose":5.57,"halted":0,"volume":81314371,"delay":0,"changeRate":-0.0017953321364453634,"floatShares":18683000000,"shares":18683000000,"eps":0.129799,"marketStatus":"休市中","change":-0.01,"latestTime":"11-13 16:08:17","open":5.57,"high":5.65,"low":5.465,"amount":453227236,"amplitude":0.033214,"askPrice":5.56,"askSize":3639000,"bidPrice":5.555,"bidSize":10000,"shortable":3,"etf":0,"ttmEps":0.153267,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794792600000},"marketStatusCode":7,"adr":0,"listingDate":1070812800000,"exchange":"SEHK","adjPreClose":5.57,"dividendRate":0.022173,"openAndCloseTimeList":[[1794533400000,1794542400000],[1794546000000,1794556800000]],"volumeRatio":1.2129193993070766,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"SBO.HK","impliedVol":0.4755,"impliedVolPercentile":0.813},"requestUrl":"/m/hq/s/01177","defaultTab":"news","newsList":[{"id":"2683541137","title":"【券商聚焦】中信建投：医药板块前三季度经营持续改善 创新药出海、CXO等主线值得关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2683541137","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683541137?lang=zh_cn&edition=full","pubTime":"2026-11-13 08:44","pubTimestamp":1794530677,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券表示，2026年前三季度医药板块经营持续改善，2027年趋势有望延续。展望2027年，创新药海外临床与注册进入密集验证期，随着出海增加、战略联盟兴起，将面对更大的市场和更复杂的竞争环境，机遇和风险并存；CXO订单转化与上游需求回暖相互促进，AIDD进一步驱动需求上升。器械业绩拐点逐步显现，中药及医药商业关注经营修复，血制品与疫苗聚焦新品、整合及出海。建议围绕创新、国际化把握机会，同时建议加大关注边际改善主线。","market":"other","thumbnail":"https://static.szfiu.com/news/20250106/ZmQ4YWNjMjZmNDUwZDg4ZTlkYjEwZTY1NmI3NmEzMzkwOTI4OTA5.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZmQ4YWNjMjZmNDUwZDg4ZTlkYjEwZTY1NmI3NmEzMzkwOTI4OTA5.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1995938","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09939","CXO","LU0540923850.HKD","LU1242518931.SGD","01093","01877","KCE","01177","159938","KURE","LU2097828714.EUR","06185","LU1794554557.SGD","LU0823426308.USD","02616","MEDX","09995","IBBQ","06978","LU2399975544.HKD","02142","LU2242644610.SGD","09688","06160","LU1226287529.USD","LU1719994722.HKD","159992","BK0276","IE00BZ08YT58.USD","01801","LU2097828474.EUR","02269","LU0320764599.SGD","LU0516423091.SGD","IE00B543WZ88.USD","BK1521","LU1226288170.HKD","09926","LU0067412154.USD","LU0819121731.USD","LU0228659784.USD","LU0140636845.USD","IE0008369823.USD","LNGR","LU0856984785.SGD","LU0417516571.SGD","WX","601066","LU0650527681.SGD","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129360879","title":"异动解读｜中国生物制药盘中下跌3.04%，乙肝创新药数据发布后资金分化","url":"https://stock-news.laohu8.com/highlight/detail?id=1129360879","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129360879?lang=zh_cn&edition=full","pubTime":"2026-11-09 14:17","pubTimestamp":1794205068,"startTime":"0","endTime":"0","summary":"11月9日，中国生物制药盘中下跌3.04%，报5.43港元，成交额3.18亿港元。消息面上，公司附属正大天晴披露国家1类创新药TQ-A3334于AASLD口头公布II期临床结果。公告称，该药为高选择性口服TLR7激动剂，此次研究评估其联合核苷（酸）类似物治疗慢性HBV感染患者的疗效与安全性；此前公司还披露，高剂量组HBsAg在48周平均下降1.8103 log10 IU/mL，且该药于10月已获CDE突破性治疗认定。股价下跌显示利好兑现后市场出现分化。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"中国生物制药走低，乙肝新药数据后资金现分歧","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682074822","title":"【港股开盘】港股开盘向好 恒指高开0.59% 药明生物（02269）涨2.90%","url":"https://stock-news.laohu8.com/highlight/detail?id=2682074822","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682074822?lang=zh_cn&edition=full","pubTime":"2026-11-09 09:25","pubTimestamp":1794187555,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股开盘向好，恒指高开0.59%，国企指数高开0.62%，恒生科技指数高开1.02%。中国生物制药高开1.96%，公司公布，附属公司正大天晴自主研发的国家1类创新药TQ-A3334“TLR7激动剂”，已于2026年美国肝病研究学会年会的最新突破性摘要平行专场，以口头报告形式公布II期临床研究结果。TQ-A3334在既往临床研究中已显示出良好的安全性和初步抗乙型肝炎病毒活性。内地股市上周五走势向下，沪综指低开低走，收市下跌1.1%，沪深两市成交额亦明显减少。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210810/MTYwMGM1ZDEwYjRjZDY4ZmI3MTk0ZDEyM2Y1MWFkMjMxODA4Mzk0Mzg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/MTYwMGM1ZDEwYjRjZDY4ZmI3MTk0ZDEyM2Y1MWFkMjMxODA4Mzk0Mzg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1995477","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1521","LU1794554557.SGD","LU0320764599.SGD","LU1242518931.SGD","LU0708995153.HKD","IE00BZ08YS42.EUR","LU0326950275.SGD","LU0516423174.USD","LU0327786744.USD","LU0320764243.SGD","LU0348825331.USD","LU0516422440.USD","LU0516423091.SGD","BK1576","02800","LU1688375341.USD","09115","LU0417516738.SGD","03037","LU0708995583.HKD","BK1589","LU0456846285.SGD","WXXWY","513600","LU0456827905.SGD","LU0029874905.USD","LU1242518857.USD","LU3063872942.SGD","LU0856984785.SGD","LU2039709279.SGD","LU0359202008.SGD","IE00BZ08YT58.USD","01177","BK1610","LU0314109678.HKD","02269","02833","LU0128526141.USD","LU0823426480.USD","LU0229945570.USD","02228","SG9999002463.SGD","SG9999011746.SGD","LU0819121731.USD","LU2476274720.SGD","KURE","HK0000165453.HKD","07500","83115","HSTECH","BK1617","LU0359201612.USD","LU0348827113.USD","BK1141","LU0561508036.HKD","LU0543330566.HKD","LU0348735423.USD","03419","HSI","82800","LU0140636845.USD","LU1813983027.USD","LU1720050803.USD","LU2778985437.USD","LU0634319403.HKD","HHImain","LU1961090484.USD","LU2399975544.HKD","LU0572944931.SGD","IE00BZ08YR35.GBP","LU0052750758.USD","LU0417516902.SGD","MCHmain","BK1191","LU0029874061.USD","LU0039217434.USD","LU0588546209.SGD","03115","LU0307460666.USD","LU0128522744.USD","SG9999002562.SGD","LU0181495838.USD","LU2476274308.USD","LU0043850808.USD","LU0823426308.USD","LU0051755006.USD","IE00B0JY6N72.USD","IE00BFMHRM44.USD","LU1880383366.USD","LU0211977185.USD","07300","LU0979878070.USD","LU0516422952.EUR","LU1328277881.USD","LU0540923850.HKD","BK1515","LU0516422366.SGD","SBHMY","07200"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682824162","title":"中国生物制药(01177)：TQ-A3334“TLR7激动剂”于2026 AASLD公布II期临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2682824162","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682824162?lang=zh_cn&edition=full","pubTime":"2026-11-09 08:14","pubTimestamp":1794183272,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 发布公告，本集团附属公司正大天晴药业集团股份有限公司自主研发的国家1类创新药TQ-A3334“TLR7激动剂”已于2026年美国肝病研究学会年会的最新突破性摘要平行专场，以口头报告形式公布II期临床研究结果。TQ-A3334是一款新型、高选择性口服Toll样受体7激动剂。TQ-A3334在既往临床研究中已显示出良好的安全性和初步抗乙型肝炎病毒活性。本次II期研究旨在评估TQ-A3334联合核甘(酸)类似物治疗慢性HBV感染患者的疗效和安全性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1520171.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01177","IE00BZ08YS42.EUR","BK1521","BK1191","IE00BZ08YR35.GBP","BK1515","BK1589","HK0000165453.HKD","IE00BZ08YT58.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187654524","title":"中国生物制药（01177）披露TQ-A3334 II期临床数据：高剂量组HBsAg 48周平均降1.8103 log10 IU/mL","url":"https://stock-news.laohu8.com/highlight/detail?id=1187654524","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187654524?lang=zh_cn&edition=full","pubTime":"2026-11-09 08:05","pubTimestamp":1794182741,"startTime":"0","endTime":"0","summary":"2026年11月9日，中国生物制药有限公司发布自愿公告称，其附属公司正大天晴药业集团股份有限公司自主研发的国家1类创新药TQ-A3334在2026年美国肝病研究学会年会“最新突破性摘要平行专场”以口头报告形式公布了II期临床研究结果。该药已于2026年10月获国家药监局药品审评中心授予突破性治疗认定。公司表示，本次II期48周数据为TQ-A3334后续临床开发提供了依据，支持其作为口服免疫调节药物进一步推进，拓展慢性HBV感染的功能性治愈选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681855633","title":"年内对外授权超百亿美元，中国生物制药开启第二增长曲线","url":"https://stock-news.laohu8.com/highlight/detail?id=2681855633","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681855633?lang=zh_cn&edition=full","pubTime":"2026-11-06 16:22","pubTimestamp":1793953320,"startTime":"0","endTime":"0","summary":"近日，中国生物制药集团（01177）公告与勃林格殷格翰达成一笔总额最高70亿美元的授权交易。这是集团2026年以来的第五笔对外授权（License-out）。集团在中报中表示，“自2026年起，对外授权合作已成为集团重要收入来源，以国际化收入为支撑的第二增长曲线正式开启”。管理层预计，2026全年创新药及对外授权收入占比约为50%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202611063924842645.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202611063924842645.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["HK0000165453.HKD","IE00BZ08YS42.EUR","BK1521","IE00BZ08YT58.USD","BK1589","BK1515","IE00BZ08YR35.GBP","BK1191","01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681802698","title":"中金：维持中国生物制药(01177.HK)“跑赢行业”评级 目标价8.90港元 与勃林格殷格翰达成战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2681802698","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681802698?lang=zh_cn&edition=full","pubTime":"2026-11-06 10:11","pubTimestamp":1793931116,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["01177","IE00BZ08YS42.EUR","BK1521","BK1191","IE00BZ08YR35.GBP","BK1515","BK1589","HK0000165453.HKD","IE00BZ08YT58.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681808748","title":"【特约大V】邓声兴：美科技股遭血洗，港股或呈震荡分化格局","url":"https://stock-news.laohu8.com/highlight/detail?id=2681808748","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681808748?lang=zh_cn&edition=full","pubTime":"2026-11-06 09:50","pubTimestamp":1793929813,"startTime":"0","endTime":"0","summary":"美科技股遭血洗，港股或呈震荡分化格局。11月4日集团与勃林格殷格翰达成协议，授权六个临床前肿瘤生物药项目，涵盖ADC及TCE两大前沿方向，首付款及近期付款3.58亿美元，潜在总额最高70亿美元，为2026年第三笔、累计第五笔重磅对外授权，年内潜在总额突破104.3亿美元、首付款超10亿美元，标志公司由引进方转为全球创新资产输出方。集团资金储备345.84亿元，并拟以44.8亿元增购正大天晴5%股权至65%，直接增厚每股盈利。","market":"us","thumbnail":"https://static.szfiu.com/news/20241108/ZjAzYmQ0ZTAxMjgwMmU1OWFmMjcwNDc3NDA4NDI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ZjAzYmQ0ZTAxMjgwMmU1OWFmMjcwNDc3NDA4NDI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1995381","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03086","BK1614","LU0417516571.SGD","BK1169","IE00BZ08YS42.EUR","BK4585","LU1328277881.USD","BK1233","IE00BZ08YR35.GBP","03034","07266","BK1589","LU0274383008.USD","02834","LU0348783233.USD","00522","07261","00341","07522","09834","LU0348735423.USD","LU0634319403.HKD","KCAI","LU0227179875.USD","LU0384037296.USD","BK1577","LU1282649810.SGD","LU1046421795.USD","LU1823568750.SGD","LU0648948544.HKD","BK1191","03455","MCHS","IE0008369823.USD","TTTN","VGT","SG9999001903.USD","LU1282649067.USD","VXUS","LU0488056044.USD","01177","LU0348766576.USD","LU0540923850.HKD","BK1147","07568","09086","LU1282649141.HKD","XLK","LU0348825331.USD","BK1610"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681884019","title":"【券商聚焦】中信建投评26 ESMO：中国创新药持续突破，竞争与差异化并存","url":"https://stock-news.laohu8.com/highlight/detail?id=2681884019","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681884019?lang=zh_cn&edition=full","pubTime":"2026-11-06 08:57","pubTimestamp":1793926628,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指，2026年欧洲内科肿瘤学会（European Society for Medical Oncology，ESMO）中，中国创新药在多瘤种领域全面发力，众多项目从早期探索迈入III期临床或BLA/NDA阶段。国内药企已在IO双抗及多抗、ADC、小分子靶向等赛道形成多线并进格局，III期阳性终点多点开花，持续产出具备国际竞争力的临床数据，标志着中国创新药研发不断从跟随创新迈向源头创新与全球引领的新阶段，行业发展逻辑从“fast-follow”迈入“first-in-class”与“best-in-class”并行的阶段。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/ZDNhNDUwNDVmY2U2MTcxMzU2NTcyMzcyOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ZDNhNDUwNDVmY2U2MTcxMzU2NTcyMzcyOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1995351","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1251922891.USD","LU0348766576.USD","01801","LU2242644610.SGD","06185","LU0540923850.HKD","BK1583","LU1807302812.USD","LU2097828714.EUR","LU0823426308.USD","LU1960683339.HKD","LU2097828474.EUR","LU0348783233.USD","LU0594300179.USD","BK1574","LU1813983027.USD","LU1152091754.HKD","LU0315179316.USD","LU0455707207.USD","LU0456827905.SGD","LU0228659784.USD","LU1242518857.USD","01877","LU1188198961.HKD","LU0417516571.SGD","02142","LU0516422952.EUR","LU1242518931.SGD","IE00BPRC5H50.USD","KURE","LU0128522744.USD","LU1226287529.USD","06160","02269","09688","LU0320764243.SGD","LU2488822045.USD","02616","09926","LU0634319403.HKD","LU0039217434.USD","BK1515","01177","01093","BK1191","601066","LU1152091168.USD","KCE","09995","LU0708995153.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681142100","title":"医药股午后继续走高 中国生物制药涨超7%百济神州涨超6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2681142100","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681142100?lang=zh_cn&edition=full","pubTime":"2026-11-05 13:48","pubTimestamp":1793857680,"startTime":"0","endTime":"0","summary":"热点栏目自选股\n数据中心\n行情中心\n资金流向\n模拟交易客户端医药股午后继续走高，创新药、CRO概念领衔。截至发稿，中国生物制药（01177）上7.18%，报5.52港元；百济神州（06160）上涨6.13%，报245.80港元；康方生物（09926）上涨4.85%，报86.50港元；信达生物（01801）上涨3.65%，报88.15港元；科伦博泰生物（06990）上涨2.89%，报455.20港元；药明康德（02359）上涨1.72%，报201.20港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-11-05/doc-inixsfae6194220.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["01177","688235","159938","BK4526","BK1500","IE00BZ08YR35.GBP","BK1588","LU0307460666.USD","BK4585","BK1515","BK0239","BK1574","LU0588546209.SGD","LU1719994722.HKD","BK4588","BK1589","09939","HK0000165453.HKD","LU1770034418.SGD","BK1161","IE00BZ08YT58.USD","ONC","BK4139","KURE","BK1583","LU0828237510.HKD","IE00BZ08YS42.EUR","LU0228659784.USD","LU2328871848.SGD","BK1191","BK1521","LU1969619763.USD","LU1303224171.USD","LU1251922891.USD","06160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681015969","title":"港股异动 | 医药股继续走强 中生制药斩获70亿美元BD领涨 前三季BD出海接近去年全年","url":"https://stock-news.laohu8.com/highlight/detail?id=2681015969","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681015969?lang=zh_cn&edition=full","pubTime":"2026-11-05 10:47","pubTimestamp":1793846861,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，医药股今早继续走高，创新药、CRO概念领衔。中国生物制药11月4日盘后公告，与跨国药企勃林格殷格翰就下一代肿瘤疗法达成重磅对外授权，覆盖6个创新药临床前项目。公司可获3.58亿美元首付款，潜在总额最高达70亿美元，刷新公司BD交易金额纪录。东方证券指出，从医药整体来看，2026年前三季度营收同比增长1.4%，归母净利润同比增长11.6%，扣非归母净利润同比增长18.3%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1518838.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1589","01177","BK1588","LU0650527681.SGD","BK4585","LU0828237510.HKD","LU0244354667.USD","LU0196878994.USD","LU2097828714.EUR","LU1303224171.USD","09939","LU0326950275.SGD","LU1251922891.USD","BK4588","BK1583","LU0149534421.HKD","LU1969619763.USD","KCAI","BK1161","LU1770034418.SGD","KURE","BK1191","01477","06160","BK1574","LU2242644610.SGD","BK1515","LU2097828631.EUR","VXUS","LU0588546209.SGD","LU0594300179.USD","BK1521","01801","LU0607220059.USD","LU0463099449.HKD","LU2328871848.SGD","159938","IE00BZ08YT58.USD","LU2097828474.EUR","LU2488822045.USD","LU1188198961.HKD","LU2097828805.USD","HK0000165453.HKD","LU1719994722.HKD","06990","LU2097828557.USD","LU1831875114.USD","LU0228659784.USD","IE00BZ08YR35.GBP","BK1500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132761019","title":"异动解读｜中国生物制药盘中上涨4.17%，70亿美元肿瘤战略合作提振情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1132761019","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132761019?lang=zh_cn&edition=full","pubTime":"2026-11-05 09:33","pubTimestamp":1793842380,"startTime":"0","endTime":"0","summary":"11月5日，中国生物制药盘中上涨4.17%，报5.395港元，成交额8125.83万港元。消息面上，公司日前与勃林格殷格翰达成肿瘤领域战略选择权及许可协议，潜在交易总额最高达70亿美元，成为股价异动的核心催化。根据公告，中国生物制药将获得3.58亿美元首付款及近期付款，合作覆盖6个临床前肿瘤项目，包括ADC和T细胞衔接器等资产，公司负责早期开发直至完成全球I期临床试验，后续还有选择权行使、开发、监管及商业化里程碑付款，并可收取最高双位数销售分成。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"中国生物制药放量上涨，70亿美元肿瘤合作引爆行情","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681018343","title":"港股异动 | 中国生物制药(01177.HK)高开逾4% 再签70亿美元BD大单 与勃林格殷格翰强化肿瘤领域战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2681018343","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681018343?lang=zh_cn&edition=full","pubTime":"2026-11-05 09:28","pubTimestamp":1793842098,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00BZ08YR35.GBP","BK1515","BK1191","BK1521","IE00BZ08YT58.USD","01177","IE00BZ08YS42.EUR","BK1589","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680042031","title":"收购礼新一年多，中国生物制药用70亿美元BD给出答案","url":"https://stock-news.laohu8.com/highlight/detail?id=2680042031","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680042031?lang=zh_cn&edition=full","pubTime":"2026-11-04 17:58","pubTimestamp":1793786339,"startTime":"0","endTime":"0","summary":"中生与勃林格殷格翰达成最高70亿美元合作，6个项目中5个来自礼新，一年多前并购礼新的管线开始集中兑现。","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3785175","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ08YT58.USD","IE00BZ08YS42.EUR","BK1589","01177","BK1191","HK0000165453.HKD","IE00BZ08YR35.GBP","BK1521","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158745793","title":"中国生物制药（01177）与勃林格殷格翰达成潜在总额70亿美元肿瘤领域战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1158745793","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158745793?lang=zh_cn&edition=full","pubTime":"2026-11-04 16:39","pubTimestamp":1793781598,"startTime":"0","endTime":"0","summary":"2026年11月4日，中国生物制药有限公司公告称，公司与勃林格殷格翰签署战略选择权及许可协议，双方将在肿瘤领域开展第二项合作，涉及抗体偶联药物及T细胞衔接器等六个临床前资产。中国生物制药将负责相关项目的早期开发，直至完成全球I期临床试验。\\n\\n交易结构显示，中国生物制药将获得3.58亿美元首付款及近期付款，并有权在未来获得最高合计70亿美元的选择权行使、开发、监管及商业化里程碑付款。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680033573","title":"中国生物制药(01177)与勃林格殷格翰达成潜在总金额70亿美元战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2680033573","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680033573?lang=zh_cn&edition=full","pubTime":"2026-11-04 16:37","pubTimestamp":1793781465,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 发布公告，本集团与勃林格殷格翰订立战略选择权及许可协议(协议)。本次与勃林格殷格翰的战略合作是本集团国际化创新战略的重要里程碑，进一步印证了本集团在下一代肿瘤疗法领域的研发实力。通过将本集团的创新平台及早期研发能力与勃林格殷格翰的全球肿瘤领域专长相结合，双方旨在充分释放该等项目的潜力，为全球患者带来创新治疗选择。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1518343.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01177","BK1589","HK0000165453.HKD","BK1191","BK1515","BK1521","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","IE00BZ08YS42.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133232754","title":"异动解读｜中国生物制药盘中上涨3.07%，乙肝创新药突破性认定催化情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1133232754","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133232754?lang=zh_cn&edition=full","pubTime":"2026-11-04 13:57","pubTimestamp":1793771856,"startTime":"0","endTime":"0","summary":"11月4日，中国生物制药盘中上涨3.07%，报5.035港元，成交额2.2亿港元。近期消息面上，公司旗下正大天晴自主研发的TQ-A3334及TQA3605被纳入突破性治疗药物程序，成为股价异动的核心催化。两款药物分别面向慢性乙肝功能性治愈及低病毒血症患者未满足需求，其中TQA3605已进入III期临床，TQ-A3334正准备进入III期，显示公司在乙肝创新药管线推进上持续取得进展。中国生物制药有限公司是一家主要从事制药业务的投资控股公司。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"中国生物制药上涨，乙肝新药获突破性认定","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175766503","title":"中国生物制药更新10月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1175766503","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175766503?lang=zh_cn&edition=full","pubTime":"2026-11-02 09:45","pubTimestamp":1793583947,"startTime":"0","endTime":"0","summary":"中国生物制药于2026年11月2日公布2026年10月的股份变动月报表。公告显示，截至10月31日，公司法定注册股本仍为30,000,000,000股普通股，总面值为750,000,000港元，与上月一致。报告期末已发行股份数量为18,682,952,230股，较上月无新增或减少。公司当月未发生新的股份发行、购回、注销或库存股变动。公告显示，截至10月末，公司股本结构总体保持稳定，并已符合适用的公众持股量要求。月报由公司秘书赖娟签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680717785","title":"【券商聚焦】中信证券：国内医药板块业绩持续修复","url":"https://stock-news.laohu8.com/highlight/detail?id=2680717785","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680717785?lang=zh_cn&edition=full","pubTime":"2026-11-02 08:40","pubTimestamp":1793580014,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券发布2027年医疗健康行业投资策略，“十五五”开局之年，医药行业首次列为国家新兴支柱产业，紧随其后的价格机制优化改革 、支持创新药械高定价、以及推动商业医疗保险发展等行业增量改革政策趋势，叠加国内医药行业在创新领域集中兑现等产业内外催化因素驱动下，该机构看到2026H1国内医药板块业绩持续修复，尤其是创新药、创新器械等新兴产业板块。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1994936","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348766576.USD","LU0455707207.USD","06821","02096","159938","06990","02268","LU1969619763.USD","02596","09939","LU0039217434.USD","03759","06996","LU1226287529.USD","KCE","01177","01530","LU0348825331.USD","LU0823426480.USD","LU2488822045.USD","03692","01093","LU0979878070.USD","LU0708995153.HKD","LU0607220059.USD","02269","09996","01951","02273","01952","09926","HK0000320264.USD","LU0588546209.SGD","02162","06078","01276","LU1064131003.USD","09966","600030","BK0028","LU1794554557.SGD","00013","01801","LU0828237510.HKD","06030","01548","IE00B031HY20.USD","KURE","06160","LU0708995583.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679257643","title":"港股异动 | 宾仕国际(01705)早盘涨超20% 公司获中国生物制药为首财团提全购","url":"https://stock-news.laohu8.com/highlight/detail?id=2679257643","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679257643?lang=zh_cn&edition=full","pubTime":"2026-10-30 11:01","pubTimestamp":1793329271,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，宾仕国际早盘涨超20%。截至发稿，涨11.11%，报1.7港元，成交额1777.97万港元。消息面上，宾仕国际宣布，要约人拟收购3亿股股份，占已发行股份总数75%，最高现金总代价2.89亿港元，相当于每股要约价约0.9634港元，较10月29日收市价1.53元折让约37.03%。公告称，要约人拟于要约结束后维持股份在联交所的上市地位。要约人由中国生物制药执行董事、执行董事委员会成员及首席执行长谢承润，副主席郑翔玲持有的 Time Innovation Global Limited 及 EJO Investment Pte. Ltd.之财团。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1515866.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK4585","IE00BZ08YR35.GBP","01177","VXUS","BK1515","BK1521","IE00BZ08YS42.EUR","HK0000165453.HKD","BK4588","BK1121","IE00BZ08YT58.USD","BK1589","01705","KCAI"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sinobiopharm.com","stockEarnings":[{"period":"1week","weight":-0.0071},{"period":"1month","weight":0.0765},{"period":"3month","weight":0.1795},{"period":"6month","weight":0.0568},{"period":"1year","weight":-0.227},{"period":"ytd","weight":-0.0782}],"compareEarnings":[{"period":"1week","weight":-0.0345},{"period":"1month","weight":-0.0278},{"period":"3month","weight":-0.0589},{"period":"6month","weight":-0.0896},{"period":"1year","weight":-0.1269},{"period":"ytd","weight":-0.0778}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"中国生物制药有限公司是一家主要从事制药业务的投资控股公司。该公司通过三个分部运营。中药现代制剂及西药分部主要从事生产、销售及配销中药现代制剂及西药产品业务。投资分部主要从事长期投资业务。其他分部主要从事相关医疗及医院业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.434783,"avgChangeRate":0.006945},{"month":2,"riseRate":0.652174,"avgChangeRate":0.056473},{"month":3,"riseRate":0.565217,"avgChangeRate":0.04606},{"month":4,"riseRate":0.478261,"avgChangeRate":0.020913},{"month":5,"riseRate":0.695652,"avgChangeRate":0.038341},{"month":6,"riseRate":0.347826,"avgChangeRate":0.004417},{"month":7,"riseRate":0.652174,"avgChangeRate":0.052281},{"month":8,"riseRate":0.434783,"avgChangeRate":-0.006702},{"month":9,"riseRate":0.434783,"avgChangeRate":-0.011268},{"month":10,"riseRate":0.521739,"avgChangeRate":0.016794},{"month":11,"riseRate":0.521739,"avgChangeRate":0.071176},{"month":12,"riseRate":0.409091,"avgChangeRate":-0.011901}],"exchange":"SEHK","name":"中国生物制药","nameEN":"SBP GROUP"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供中国生物制药(01177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"中国生物制药,01177,中国生物制药股票,中国生物制药股票老虎,中国生物制药股票老虎国际,中国生物制药行情,中国生物制药股票行情,中国生物制药股价,中国生物制药股市,中国生物制药股票价格,中国生物制药股票交易,中国生物制药股票购买,中国生物制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供中国生物制药(01177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}